Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alfonso Aguaron"'
Autor:
Valeria Sebri, Chiara Marzorati, Patrizia Dorangricchia, Dario Monzani, Roberto Grasso, Arsela Prelaj, Leonardo Provenzano, Laura Mazzeo, Andra Diana Dumitrascu, Jana Sonnek, Marlen Szewczyk, Iris Watermann, Francesco Trovò, Nina Dollis, Evangelos Sarris, Marina Chiara Garassino, Christine M. Bestvina, Alessandra Pedrocchi, Emilia Ambrosini, Sokol Kosta, Enriqueta Felip, Mireia Soleda, Aina Arbusà Roca, Jose Rodríguez‐Morató, Alessandro Nuara, Yonah Lourie, Melissa Fernandez‐Pinto, Alfonso Aguaron, Gabriella Pravettoni
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Introduction To date, lung cancer is one of the most lethal diagnoses worldwide. A variety of lung cancer treatments and modalities are available, which are generally presented during the patient and doctor consultation. The implementation o
Externí odkaz:
https://doaj.org/article/ed074b66fd67427fb27af9774867cbe3
Autor:
Pasquale Varriale, Borna Müller, Grégory Katz, Lorraine Dallas, Alfonso Aguaron, Marion Azoulai, Nicolas Girard
Publikováno v:
JMIR Formative Research, Vol 7, p e37190 (2023)
BackgroundWhile the lung cancer (LC) treatment landscape has rapidly evolved in recent years, easing symptom burden and treatment side effects remain central considerations in disease control. ObjectiveThe aim of this study was to assess the relativ
Externí odkaz:
https://doaj.org/article/bef9be0f86fe4d7998cd75b07a33acba
Autor:
Arsela Prelaj, Monica Ganzinelli, Francesco Trovo’, Laila C. Roisman, Alessandra Laura Giulia Pedrocchi, Sokol Kosta, Marcello Restelli, Emilia Ambrosini, Massimo Broggini, Gabriella Pravettoni, Dario Monzani, Alessandro Nuara, Ramon Amat, Nikos Spathas, Michael Willis, Alexander Pearson, James Dolezal, Laura Mazzeo, Sabina Sangaletti, Ana Maria Correa, Alfonso Aguaron, Iris Watermann, Crina Popa, Giulia Raimondi, Tiziana Triulzi, Stefan Steurer, Giuseppe Lo Russo, Helena Linardou, Nir Peled, Enriqueta Felip, Martin Reck, Marina Chiara Garassino
Publikováno v:
Prelaj, A, Ganzinelli, M, Trovo’, F, Roisman, L C, Pedrocchi, A L G, Kosta, S, Restelli, M, Ambrosini, E, Broggini, M, Pravettoni, G, Monzani, D, Nuara, A, Amat, R, Spathas, N, Willis, M, Pearson, A, Dolezal, J, Mazzeo, L, Sangaletti, S, Correa, A M, Aguaron, A, Watermann, I, Popa, C, Raimondi, G, Triulzi, T, Steurer, S, Lo Russo, G, Linardou, H, Peled, N, Felip, E, Reck, M & Garassino, M C 2023, ' The EU-funded I 3 LUNG Project : Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy ', Clinical Lung Cancer, vol. 24, no. 4, pp. 381-387 . https://doi.org/10.1016/j.cllc.2023.02.005
Although immunotherapy (IO) has changed the paradigm for the treatment of patients with advanced non-small cell lung cancers (aNSCLC), only around 30% to 50% of treated patients experience a long-term benefit from IO. Furthermore, the identification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e66a29b8ddae73ed36c22ff8b32b33b7
https://vbn.aau.dk/da/publications/0c050501-8e87-4840-82ca-a3fec28edc50
https://vbn.aau.dk/da/publications/0c050501-8e87-4840-82ca-a3fec28edc50
Autor:
Borna, Müller, Pasquale, Varriale, Grégory, Katz, Lorraine, Dallas, Alfonso, Aguaron, Marion, Azoulai, Nicolas, Girard
Publikováno v:
JMIR formative research.
While the LC treatment landscape has rapidly evolved in recent years, easing symptom burden and treatment side effects remains a central consideration in disease control.The aim of this study was to assess the relative importance of dimensions of lun